Collateral effects of antiarrhythmics in pediatric age

Current Pharmaceutical Design

Volumn 14, Issue 8, 2008, Pages 782-787

  Sulafa Ali, Khalid M ^a  

^a UNIVERSITY OF KHARTOUM   (Sudan)

Author keywords

Antiarrhythmic; Children; Collateral effects

Indexed keywords

ADENOSINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRETYLIUM; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CYCLOSPORIN; DIGITALIS; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; ENCAINIDE; ESMOLOL; FLECAINIDE; IBUTILIDE; LIDOCAINE; MAGNESIUM; MEXILETINE; MORACIZINE; NADOLOL; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; TOCAINIDE; UNINDEXED DRUG; VERAPAMIL;

ABDOMINAL PAIN; ABNORMAL THINKING; APNEA; ARTHRITIS; ATRIOVENTRICULAR BLOCK; ATRIOVENTRICULAR CONDUCTION; BLURRED VISION; BONE MARROW APLASIA; BRADYCARDIA; BRONCHOSPASM; CLINICAL TRIAL; CONSTIPATION; CORNEA DISEASE; CORNEAL MICRODEPOSIT; DIARRHEA; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FLUSHING; GLAUCOMA; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART PROARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERACTIVITY; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; IRRITABILITY; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LUNG FIBROSIS; LUPUS LIKE SYNDROME; MONOTHERAPY; NAUSEA; NEUROPATHY; OPTIMAL DRUG DOSE; PEDIATRIC CARDIOLOGY; PERICARDITIS; PERIPHERAL NEUROPATHY; PERSONALITY DISORDER; PHOTOSENSITIVITY; PIGMENT DISORDER; PRIORITY JOURNAL; QT PROLONGATION; REENTRY TACHYCARDIA; RESPIRATORY DISTRESS; REVIEW; SEIZURE; SHOCK; SIDE EFFECT; SINUS ARREST; SINUS BRADYCARDIA; SINUS NODE DYSFUNCTION; SLEEP; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; SYNCOPE; TERATOGENICITY; THYROID DISEASE; TORSADE DES POINTES; TREMOR; URINE RETENTION; VISUAL DISORDER; WHEEZING; WOLFF PARKINSON WHITE SYNDROME; XEROSTOMIA;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CHILD; DRUG INTERACTIONS; HUMANS;

EID: 44349119162     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784007743     Document Type: Review

References (53)

1. Luedtke SA, Kuhn RJ, McCaffrey FM. Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry. Ann Pharmacother 1997; 10: 1227-43.
2. Vaughan Williams EM: In: Sandoe E, Flensted-Jensen E, Olesen K Eds, Classification of antiarrhythmic drugs, Cardiac Arrhythmias. Sweden, Astra, Sodertaije 1981; 449-72.
3. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831-51.
4. Dilaveris PE. Molecular predictors of drug-induced prolongation of the QT interval. Curr Med Chem Cardiovasc Hematol Agents 2005; 2: 105-18.
5. Lehtonen A, Fodstad H, Laitinen-Forsblom P, Toivonen L, Kontula K, Swan H. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart. Rhythm 2007; 5: 603-7.
6. Roden DM Antiarrhythmic drugs: From mechanisms to clinical practice. Heart 2000; 84: 339-46.
7. Paul T, Bertram H, Bökenkamp R, Hausdorf G. Supraventricular tachycardia in infants, children and adolescents: Diagnosis, and pharmacological and interventional therapy. Paediatr Drugs 2000; 3: 171-81.
8. Radford D. Side effects of verapamil in infants. Arch Dis Child 1983; 58: 465-6.
9. Epstein ML, Kiel EA, Victoria BE. Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia. Pediatrics 1985; 75: 737-40.
10. Byrum CJ, Wahl RA, Behrendt DM, Dick M. Ventricular fibrillation associated with use of digitals in a newborn infant with WPW. Pediatrics 1982; 3: 400-3.
11. Luedike SA, Kuhn RJ, McCaffrey FM. Pharmacologic managemennt of supraventricular tachycardias in children. Part, 1: Wolff-Parkinson-White and atrioventricular nodal reentry. Ann Pharmacother 1997; 10: 1227-43.
12. Satrasburger JF. Antiarrhythmic drugs. in: Garso A Jr, Bricker JT, McNamar DG Eds. The science and practice of pediatric cardiology. Philadelphia, Lea and Febiger 1990; 2126-34.
13. Moak JP. Pharmacology and electrophysiology and antiarrhythmic drugs. In: Gillette PC. Garcon A Jr. Eds. Pediatric arrhythmias: electrophysiology and pacing. Philadelphia, W.B. Saunders Company 1990; 37-115.
14. Price JF, Kertesz NJ, Snyder CS, Friedman RA, Fenrich AL. Flecainide and sotalol: A new combination therapy for refractory supraventricular tachycardia in children <1 year of age. J Am Coll Cardiol 2002; 3: 517-20.
15. Fenrich AL Jr, Perry JC, Friedman RA. Flecainide and amiodarone: combined therapy for refractory tachyarrhythmias in infancy. J Am Coll Cardiol 1995; 5: 1195-8.
16. Boutitie F, Boissel JP, Connolly SJ, Camm AJ, Cairns JA, Julian DG, et al. Amiodarone interaction with β-blockers analysis of the merged EMIAT (European Myocardial infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial infarction Trial) Databases. Circulation 1999; 99: 2268-75.
17. Zalzstein E, Koren G, Bryson SM, Freedom RM. interaction between digoxin and propatenone in children. J Pediatr 1990; 116: 310-2.
18. Jouannic JM, Delahaye S, Le Bidois J, Fermont L, Villain E, Dommergues M, et al. Results of prenatal management of fetuses with supraventricular tachycardia. A series of 66 cases. J Gynecol Obstet Biol Reprod (Paris) 2003; 4: 3388-44.
19. Till J, Shinebourne EA, Rigby ME, Clarke B, Ward DE, Rawland E. Efficacy and safety of adenosine in the treatment of supraventricular tachycardia in infantsand children. Br Heart J 1989; 62: 204-11.
20. Paul T, Pfammatter JP. Adenosine: An effective and safe antiarrhythmic drug in pediatrics. Pediatr Cardiol 1997; 2: 118-26.
21. Perry JC, McQuinn RL, Smith RT, Gothing C, Fredell P, Garson A. Flecainide acetate for resistant arrhythmias in the young: Efficacy and pharmacokinetics. JAm Coll Cardiol 1989; 14: 185-91.
22. Ziegler V, Gillette PC, Ross BA, Ewing L. Flecainide for supraventricular and ventricular arrhythmias in children and young adults. Am J Cardiol 1988; 62: 818-20.
23. Till J, Herxcheimer A. Death of a child with supraventricular tachycardia. Lancet 1992; 339: 1597-8.
24. Fish FA, Gillette PC, Benson DW. For the pediatric electrophysiology group. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. J Am Coll Cardiol 1991; 18: 356-65.
25. Perry JC, Garson A. Flecainide acetate for treatment of tachyarrhythmias in children: Review of world literature on efficacy, safety and dosing. Am Heart J 1992; 124: 1614-21.
26. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl i Med 1989; 321: 406-12.
27. Janousek J, Paul T. Safety of oral propafenone in the treatment of arrhythmias in infants and children (European retrospective multicenter study). Working Group on Pediatric Arrhythimias and Electrophysiology of the Association of European Pediatric Cardiologists. Am J Cardiol 1998; 9: 1121-4.
28. Reimer A, Paul T, Kallfelz HC. Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmia. Am J Cardiol 1991; 68: 741-4.
29. Guccione P, Drago F, Di Donato RM, Cicini MP, Pasquini L, Marino B, et al. Oral propafenone therapy for children with arrhythmias: efficacy and adverse effects in midterm follow-up. Am Heart J 1991; 122: 1022-7.
30. Coumel P, Lucet V, Ngoc DD. The use of antiodarone in children. PACE 1983; 6: 930-9.
31. Coumel,P, Fidelle,J.Amiodarone in the treatment of cardiac arrhytmias in children: One hundred thirty-five cases. Am J Cardiol 1992; 69: 751-4
32. Garson A Jr, Gillete PC, McVey P, Hesslein PS, Porter Ci, Angell LK. et al. Amiodarone treatment of critical arrhythmias in children and young adults. J Am Coll Cardiol 1984; 4: 749-55.
33. Bucknall CA, Keeton BR, Curry PVL, Tynan Mi, Sutherland GR, Holt DW. intravenous and oral antiodarone for arrhythimas in children. Br Heart J 1986; 56: 278-84.
34. Till JA, Baxendall M, Benetar A. Acceleration of the ventricular response to atrial flutter by armoidarone In an infant with Walff- Parkinson-White syndrome. Br Heart J 1993: 70: 64-7.
35. Goccionee P, Paul T, Garcon A Jr. Long-term foll ow up of amiodarone therapy in the young: Continued efficacy, unimpaired growth and moderate side effects. J Am Coll Cardiol 1990; 15: 1118-24.
36. Laird WP, Snyder CS, Kertesz NJ, Friedman RA, Miller D, Fenrich AL. Use of a amiodarone for postoperative junctional ectopic tachycardia in the children. Pediatr Cardiol 2003; 2: 133-7.
37. Pongiglione G, Strasburger J, Deal BJ, Benson DW. Use of amiodarone for short-term and adjuvant therapy in young patient. Am J Cardiol 1991; 68: 603-8.
38. Wiest DB, Trippel DI, Gillette PC, Garner SS. Pharmacokinets of esmolo in children. Clin Pharmacol Ther 1991; 49: 618-23.
39. Mehta AV, Chidambaram B. Efficacy tachyacardia in children. J Am Coll Cardiol 1992; 19: 630-5.
40. Ko JK, Ban JE, Kim YH, Park IS. Long-term efficacy of atenolol for atrioventricular reciprocating tachycardia in children less than 5 years old. Ped Cardiol 2004; 25: 97-101.
41. Tripple DI, Gillette PC. Atenolol in children with ventricular arrhythmias. Am Heart J 1990; 11912-6.
42. Maragnes P, Tripple M, Fournier A. Effectiveness of oral sotalol for treatment of pediatric arrhythmias. Am J Cardiol 1992; 69: 751-4.
43. Pfammatter JP, Paul T. New antiarrhythmic drug in pediatric use: sotalol. Pediatr Cardiol 1997; 1: 28-34.
44. Moffett BS, Cannon BC, Friedman RA, Kertesz NJ. Therapeutic levels of intravenous procainamide in neonates: A retrospective assessment. Pharmacotherapy 2006; 12: 1687-93.
45. Mandapati R, Byrum CJ, Kavey RE, Smith FC, Kveselis DA, Hannan WP, et al. Procainamide for rate control of postsurgical junctional tachycardia. Pediatr Cardiol 2000; 2: 123-8.
46. Burckart GJ, Marin-Garcia J. Quinidine dosage in children using populationestimates. Pediatr Cardiol 1986; 6: 269-73.
47. Webb CL, Dick M, Rocchini AP, Snider AR, Crowley DC, Beekman RH, et al. Quinidine syncope in children. J Am Coll Cardiol 1987; 9: 1031-7.
48. Moak JP, Smith RT, Garcon A Jr. Newer antiarrhythmic drugs in children. Am Heart J 1987; 13: 179-85.
49. Mehta AV, Subrahmanyam AB, Long JB, Kanter RJ. Experience with moricizine HC1 in children with supraventricular tachycardia. Int J Cardiol 1996; 1: 31-5.
50. Pfammatter JP, Stocker FP. Re-entrant supraventricular tachycardia in infancy: Current role of prophylactic digoxin treatment. Eur J Pediatr 1998; 2: 101-6.
51. Pinksy WW, Jacobsen JR, Gillette PC, Adams J, Monroe L, McNamara DG. Dosage of digoxin in premature infants. J Pediatr 1979; 96 639-42.
52. Ratnapalan S, Griffiths K, Kostei AM, Benson L, Koren G. Digoxin-carvedolol interactions in children. J Pediatr 2003; 5: 572-4.
53. Hoyer AW, Balaji S. The safety and efficacy of ibutilide in children and in patients with congenital heart disease. Pacing Clin Electrophysiol 2007; 8: 1003-8.